Search

Your search keyword '"Prat, Aleix"' showing total 1,401 results
Start Over Author "Prat, Aleix"
1,401 results on '"Prat, Aleix"'

51. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Curigliano, Giuseppe, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun-Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, Poortmans, Philip, Prat, Aleix, Regan, Meredith, Rubio, Isabella, Rugo, Hope, Rutgers, Emiel, Sedlmayer, Felix, Semiglazov, Vladimir, Senn, Hans-Joerg, Shao, Zhiming, Spanic, Tanja, Tesarova, Petra, Thürlimann, Beat, Tjulandin, Sergei, Toi, Masakazu, Trudeau, Maureen, Turner, Nicholas, Vaz Luis, Inez, Viale, Giuseppe, Watanabe, Toru, Weber, Walter P., Winer, Eric P., Xu, Binghe, Burstein, H.J., Curigliano, G., Thürlimann, B., Weber, W.P., Poortmans, P., Regan, M.M., Senn, H.J., Winer, E.P., and Gnant, M.

Published
2021
Full Text
View/download PDF

52. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

Author

Pérez-García, José Manuel, Gebhart, Geraldine, Ruiz Borrego, Manuel, Stradella, Agostina, Bermejo, Begoña, Schmid, Peter, Marmé, Frederik, Escrivá-de-Romani, Santiago, Calvo, Lourdes, Ribelles, Nuria, Martinez, Noelia, Albacar, Cinta, Prat, Aleix, Dalenc, Florence, Kerrou, Khaldoun, Colleoni, Marco, Afonso, Noemia, Di Cosimo, Serena, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier, and Llombart-Cussac, Antonio

Published
2021
Full Text
View/download PDF

53. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Author

Rugo, Hope S, Lerebours, Florence, Ciruelos, Eva, Drullinsky, Pamela, Ruiz-Borrego, Manuel, Neven, Patrick, Park, Yeon Hee, Prat, Aleix, Bachelot, Thomas, Juric, Dejan, Turner, Nicholas, Sophos, Nickolas, Zarate, Juan Pablo, Arce, Christina, Shen, Yu-Ming, Turner, Stuart, Kanakamedala, Hemanth, Hsu, Wei-Chun, and Chia, Stephen

Published
2021
Full Text
View/download PDF

54. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Author

Mayer, Erica L, Dueck, Amylou C, Martin, Miguel, Rubovszky, Gabor, Burstein, Harold J, Bellet-Ezquerra, Meritxell, Miller, Kathy D, Zdenkowski, Nicholas, Winer, Eric P, Pfeiler, Georg, Goetz, Matthew, Ruiz-Borrego, Manuel, Anderson, Daniel, Nowecki, Zbigniew, Loibl, Sibylle, Moulder, Stacy, Ring, Alistair, Fitzal, Florian, Traina, Tiffany, Chan, Arlene, Rugo, Hope S, Lemieux, Julie, Henao, Fernando, Lyss, Alan, Antolin Novoa, Silvia, Wolff, Antonio C, Vetter, Marcus, Egle, Daniel, Morris, Patrick G, Mamounas, Eleftherios P, Gil-Gil, Miguel J, Prat, Aleix, Fohler, Hannes, Metzger Filho, Otto, Schwarz, Magdalena, DuFrane, Carter, Fumagalli, Debora, Theall, Kathy Puyana, Lu, Dongrui Ray, Bartlett, Cynthia Huang, Koehler, Maria, Fesl, Christian, DeMichele, Angela, and Gnant, Michael

Published
2021
Full Text
View/download PDF

56. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Author

Prat, Aleix, Guarneri, Valentina, Paré, Laia, Griguolo, Gaia, Pascual, Tomás, Dieci, Maria V, Chic, Núria, González-Farré, Blanca, Frassoldati, Antonio, Sanfeliu, Esther, Cejalvo, Juan M, Muñoz, Montserrat, Bisagni, Giancarlo, Brasó-Maristany, Fara, Urso, Loredana, Vidal, Maria, Brandes, Alba A, Adamo, Barbara, Musolino, Antonino, Miglietta, Federica, Conte, Benedetta, Oliveira, Mafalda, Saura, Cristina, Pernas, Sònia, Alarcón, Jesús, Llombart-Cussac, Antonio, Cortés, Javier, Manso, Luis, López, Rafael, Ciruelos, Eva, Schettini, Francesco, Villagrasa, Patricia, Carey, Lisa A, Perou, Charles M, Piacentini, Federico, D'Amico, Roberto, Tagliafico, Enrico, Parker, Joel S, and Conte, Pierfranco

Published
2020
Full Text
View/download PDF

57. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Author

Prat, Aleix, Saura, Cristina, Pascual, Tomás, Hernando, Cristina, Muñoz, Montserrat, Paré, Laia, González Farré, Blanca, Fernández, Pedro L, Galván, Patricia, Chic, Núria, González Farré, Xavier, Oliveira, Mafalda, Gil-Gil, Miguel, Arumi, Miriam, Ferrer, Neus, Montaño, Alvaro, Izarzugaza, Yann, Llombart-Cussac, Antonio, Bratos, Raquel, González Santiago, Santiago, Martínez, Eduardo, Hoyos, Sergio, Rojas, Beatriz, Virizuela, Juan Antonio, Ortega, Vanesa, López, Rafael, Céliz, Pamela, Ciruelos, Eva, Villagrasa, Patricia, and Gavilá, Joaquín

Published
2020
Full Text
View/download PDF

58. Supplementary Table S12 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

59. Supplementary Figure S1 from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

60. Data from SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

Author

Conte, Benedetta, primary, Boni, Luca, primary, Bisagni, Giancarlo, primary, Durando, Antonio, primary, Sanna, Giovanni, primary, Gori, Stefania, primary, Garrone, Ornella, primary, Tamberi, Stefano, primary, De Placido, Sabino, primary, Schettini, Francesco, primary, Pazzola, Antonio, primary, Ponzone, Riccardo, primary, Montemurro, Filippo, primary, Lunardi, Gianluigi, primary, Notaro, Rosario, primary, De Angioletti, Maria, primary, Turletti, Anna, primary, Mansutti, Mauro, primary, Puglisi, Fabio, primary, Frassoldati, Antonio, primary, Porpiglia, Mauro, primary, Fabi, Alessandra, primary, Generali, Daniele, primary, Scognamiglio, Giovanni, primary, Rossi, Maura, primary, Brasó-Maristany, Fara, primary, Prat, Aleix, primary, Cardinali, Barbara, primary, Piccioli, Patrizia, primary, Serra, Martina, primary, Lastraioli, Sonia, primary, Bighin, Claudia, primary, Poggio, Francesca, primary, Lambertini, Matteo, primary, and Del Mastro, Lucia, primary

Published
2023
Full Text
View/download PDF

61. Intrinsic subtype and overall survival of patients with advanced HR+/HER2− breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7

Author

Prat, Aleix, primary, Solovieff, Nadia, additional, Andre, Fabrice, additional, O’Shaughnessy, Joyce, additional, Cameron, David A., additional, Janni, Wolfgang, additional, Sonke, Gabe S., additional, Yap, Yoon-Sim, additional, Yardley, Denise A., additional, Partridge, Ann H., additional, Thuerigen, Astrid, additional, Zarate, Juan Pablo, additional, Lteif, Agnes, additional, Su, Fei, additional, and Carey, Lisa A., additional

Published
2023
Full Text
View/download PDF

62. 582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

Author

Olea, Julian, primary, Dadrastoussi, Homa, additional, Hernandez, Eduardo Fernandez, additional, Martinez, Hugo Lara, additional, Wu, Kaijin, additional, Loghmani, Houra, additional, Heineman, Thomas, additional, Trauger, Richard, additional, Coffey, Matt, additional, Salvador, Fernando, additional, Gavilá, Joaquín, additional, Pascual, Tomás, additional, Manso, Luis, additional, Prat, Aleix, additional, Merchant, Akil, additional, and Kelly, Kevin, additional

Published
2023
Full Text
View/download PDF

63. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

Author

Guedan, Sonia, primary, Andreu-Saumell, Irene, additional, Rodriguez-Garcia, Alba, additional, Gimenez-Alejandre, Marta, additional, Castellsagué, Joan, additional, Mühlgrabner, Vanessa, additional, Brasó-Maristany, Fara, additional, Calderon, Hugo, additional, Marzal, Berta, additional, Colell, Salut, additional, Nuding, Mara, additional, Soria-Castellano, Marta, additional, Barbao, Paula, additional, Prat, Aleix, additional, Urbano-Ispizua, Alvaro, additional, and Huppa, Johannes, additional

Published
2023
Full Text
View/download PDF

64. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

Author

De Mattos-Arruda, Leticia, Cortes, Javier, Blanco-Heredia, Juan, Tiezzi, Daniel G., Villacampa, Guillermo, Gonçalves-Ribeiro, Samuel, Paré, Laia, Souza, Carla Anjos, Ortega, Vanesa, Sammut, Stephen-John, Cusco, Pol, Fasani, Roberta, Chin, Suet-Feung, Perez-Garcia, Jose, Dienstmann, Rodrigo, Nuciforo, Paolo, Villagrasa, Patricia, Rubio, Isabel T., Prat, Aleix, and Caldas, Carlos

Published
2021
Full Text
View/download PDF

65. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Author

Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, and Prat, Aleix

Published
2021
Full Text
View/download PDF

68. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Author

Schmid, Peter, Sablin, Marie-Paule, Bergh, Jonas, Im, Seock-Ah, Lu, Yen-Shen, Martínez, Noelia, Neven, Patrick, Lee, Keun Seok, Morales, Serafín, Pérez-Fidalgo, J. Alejandro, Adamson, Douglas, Gonçalves, Anthony, Prat, Aleix, Jerusalem, Guy, Schlieker, Laura, Espadero, Rosa-Maria, Bogenrieder, Thomas, Huang, Dennis Chin-Lun, Crown, John, and Cortés, Javier

Published
2021
Full Text
View/download PDF

69. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

Author

Pascual, Tomás, Oliveira, Mafalda, Villagrasa, Patricia, Ortega, Vanesa, Paré, Laia, Bermejo, Begoña, Morales, Serafín, Amillano, Kepa, López, Rafael, Galván, Patricia, Canes, Jordi, Salvador, Fernando, Nuciforo, Paolo, Rubio, Isabel T., Llombart-Cussac, Antonio, Di Cosimo, Serena, Baselga, José, Harbeck, Nadia, Prat, Aleix, and Cortés, Javier

Published
2021
Full Text
View/download PDF

71. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Author

Martínez-Sáez, Olga, Pascual, Tomás, Brasó-Maristany, Fara, Chic, Nuria, González-Farré, Blanca, Sanfeliu, Esther, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Anna Belén, Schettini, Francesco, Conte, Benedetta, Vidal, Maria, Adamo, Barbara, Martínez, Antoni, Muñoz, Montserrat, Moreno, Reinaldo, Villagrasa, Patricia, Salvador, Fernando, Ciruelos, Eva M., Faull, Iris, Odegaard, Justin I., and Prat, Aleix

Published
2021
Full Text
View/download PDF

72. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

Author

Sanz-Moreno, Adrián, Palomeras, Sonia, Pedersen, Kim, Morancho, Beatriz, Pascual, Tomas, Galván, Patricia, Benítez, Sandra, Gomez-Miragaya, Jorge, Ciscar, Marina, Jimenez, Maria, Pernas, Sonia, Petit, Anna, Soler-Monsó, María Teresa, Viñas, Gemma, Alsaleem, Mansour, Rakha, Emad A., Green, Andrew R., Santamaria, Patricia G., Mulder, Celine, Lemeer, Simone, Arribas, Joaquin, Prat, Aleix, Puig, Teresa, and Gonzalez-Suarez, Eva

Published
2021
Full Text
View/download PDF

73. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

Author

Giuliano, Mario, Schettini, Francesco, Rognoni, Carla, Milani, Manuela, Jerusalem, Guy, Bachelot, Thomas, De Laurentiis, Michelino, Thomas, Guglielmo, De Placido, Pietro, Arpino, Grazia, De Placido, Sabino, Cristofanilli, Massimo, Giordano, Antonio, Puglisi, Fabio, Pistilli, Barbara, Prat, Aleix, Del Mastro, Lucia, Venturini, Sergio, and Generali, Daniele

Published
2019
Full Text
View/download PDF

74. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

Author

Garcia-Recio, Susana, Thennavan, Aatish, East, Michael P., Parker, Joel S., Cejalvo, Juan M., Garay, Joseph P., Hollern, Daniel P., He, Xiaping, Mott, Kevin R., Galvan, Patricia, Fan, Cheng, Selitsky, Sara R., Coffey, Alisha R., Marron, David, Braso-Maristany, Fara, Burgues, Octavio, Albanell, Joan, Rojo, Federico, Lluch, Ana, de Duenas, Eduardo Martinez, Rosen, Jeffery M., Johnson, Gary L., Carey, Lisa A., Prat, Aleix, and Perou, Charles M.

Subjects
Lapatinib -- Analysis, Genes -- Analysis, RNA sequencing -- Analysis, Breast cancer -- Development and progression, Cancer metastasis -- Development and progression, Gene expression -- Analysis, RNA -- Analysis, Health care industry
Abstract

Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise to HER2-enriched (HER2E) subtype metastases, but remain clinically HER2 negative (cHER2). By testing the unique genetic and transcriptomic features of these cases, we developed the hypothesis that FGFR4 likely participates in this subtype switching. To evaluate this, we developed 2 FGFR4 genomic signatures using a patient-derived xenograft (PDX) model treated with an FGFR4 inhibitor, which inhibited PDX growth in vivo. Bulk tumor gene expression analysis and single-cell RNA sequencing demonstrated that the inhibition of FGFR4 signaling caused molecular switching. In the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohort, FGFR4-induced and FGFR4-repressed signatures each predicted overall survival. Additionally, the FGFR4-induced signature was an independent prognostic factor beyond subtype and stage. Supervised analysis of 77 primary tumors with paired metastases revealed that the FGFR4-induced signature was significantly higher in luminal/[ER.sup.+] tumor metastases compared with their primaries. Finally, multivariate analysis demonstrated that the FGFR4-induced signature also predicted site-specific metastasis for lung, liver, and brain, but not for bone or lymph nodes. These data identify a link between FGFR4-regulated genes and metastasis, suggesting treatment options for FGFR4-positive patients, whose high expression is not caused by mutation or amplification., Introduction Treating metastatic breast cancer patients has become increasingly complex, in part due to the large number of therapeutic options in the second- and third-line settings. Tumor heterogeneity imparts another [...]

Published
2020
Full Text
View/download PDF

75. The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver

Author

Hruschka, Natascha, Kalisz, Mark, Subijana, Maria, Graña-Castro, Osvaldo, Del Cano-Ochoa, Francisco, Brunet, Laia Paré, Chernukhin, Igor, Sagrera, Ana, De Reynies, Aurelien, Kloesch, Bernhard, Chin, Suet-Feung, Burgués, Octavio, Andreu, David, Bermejo, Begoña, Cejalvo, Juan Miguel, Sutton, Joe, Caldas, Carlos, Ramón-Maiques, Santiago, Carroll, Jason S., Prat, Aleix, Real, Francisco X., and Martinelli, Paola

Published
2020
Full Text
View/download PDF

79. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Author

Duruisseaux, Michäel, Martínez-Cardús, Anna, Calleja-Cervantes, Maria E, Moran, Sebastian, Castro de Moura, Manuel, Davalos, Veronica, Piñeyro, David, Sanchez-Cespedes, Montse, Girard, Nicolas, Brevet, Marie, Giroux-Leprieur, Etienne, Dumenil, Coraline, Pradotto, Monica, Bironzo, Paolo, Capelletto, Enrica, Novello, Silvia, Cortot, Alexis, Copin, Marie-Christine, Karachaliou, Niki, Gonzalez-Cao, Maria, Peralta, Sergio, Montuenga, Luis M, Gil-Bazo, Ignacio, Baraibar, Iosune, Lozano, Maria D, Varela, Mar, Ruffinelli, Jose C, Palmero, Ramon, Nadal, Ernest, Moran, Teresa, Perez, Lidia, Ramos, Immaculada, Xiao, Qingyang, Fernandez, Agustin F, Fraga, Mario F, Gut, Marta, Gut, Ivo, Teixidó, Cristina, Vilariño, Noelia, Prat, Aleix, Reguart, Noemi, Benito, Amparo, Garrido, Pilar, Barragan, Isabel, Emile, Jean-François, Rosell, Rafael, Brambilla, Elisabeth, and Esteller, Manel

Published
2018
Full Text
View/download PDF

80. Identification of a novel prognostic gene signature in a clear cell renal cell carcinoma (ccRCC) population using an integrated multi-study single-cell RNAseq dataset.

Author

García-Esteve, Samuel, Jiménez, Natalia, Aversa, Caterina, Ferrer-Mileo, Laura, Garcia de Herreros, Marta, Fernandez-Mañas, Laia, González-Aguado, Laura, Rubio-Pérez, Carlota, Cobo-Diego, Inés, Mazariegos, Manuel, Prat, Aleix, Mellado-González, Begoña, and Reig-Torras, Òscar

Published
2024
Full Text
View/download PDF

81. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.

Author

Dieci, Maria Vittoria, Conte, PierFranco, Bisagni, Giancarlo, Bartolini, Stefania, Frassoldati, Antonio, Generali, Daniele, Piacentini, Federico, Griguolo, Gaia, Tagliafico, Enrico, Maristany, Fara Brasó, Chic, Nuria, Paré, Laia, Miglietta, Federica, Vicini, Roberto, D'Amico, Roberto, Balduzzi, Sara, Prat, Aleix, and Guarneri, Valentina

Subjects
HER2 positive breast cancer, DISEASE risk factors, HORMONE receptor positive breast cancer, METASTASIS, PATIENT experience, COMPETING risks
Abstract

Background Even with contemporary treatment strategies, more than 10% of HER2-positive early stage breast cancer patients may experience distant metastasis as first event during follow-up. Tools for predicting unique patterns of metastatic spread are needed to plan personalized surveillance. We evaluated how molecular heterogeneity affects the pattern of distant relapse in HER2-positive breast cancer. Methods A total of 677 HER2-positive stage I-III breast cancer patients from ShortHER trial, Cher-LOB trial, and 2 institutional cohorts were included. PAM50 molecular subtypes and research-based HER2DX scores were evaluated. The cumulative incidence of distant relapse as the first event (any site and site specific) was evaluated using competing risk analysis. Median follow-up was 8.4 years. Tests of statistical significance are 2-sided. Results Stage III and high HER2DX risk score identified patients at the highest risk of distant relapse as first event (10-year incidence 24.5% and 19.7%, respectively). Intrinsic molecular subtypes were associated with specific patterns of metastatic spread: compared with other subtypes, HER2-enriched tumors were more prone to develop brain metastases (10-year incidence 3.8% vs 0.6%, P  = .005), basal-like tumors were associated with an increased risk of lung metastases (10-year incidence 11.1% vs 2.6%, P  = .001), and luminal tumors developed more frequently bone-only metastases (10-year incidence 5.1% vs 2.0%, P  = .042). When added to stage or HER2DX risk score in competing risk regression models, intrinsic subtype maintained an independent association with site-specific metastases. Conclusions The integration of intrinsic molecular subtypes with stage or HER2DX risk score predicts site-specific metastatic risk in HER2-positive breast cancer, with potential implications for personalized surveillance and clinical trials aimed at preventing site-specific recurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

82. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

Author

Dieci, Maria Vittoria, primary, Conte, PierFranco, additional, Bisagni, Giancarlo, additional, Bartolini, Stefania, additional, Frassoldati, Antonio, additional, Generali, Daniele, additional, Piacentini, Federico, additional, Griguolo, Gaia, additional, Tagliafico, Enrico, additional, Brasó Maristany, Fara, additional, Chic, Nuria, additional, Paré, Laia, additional, Miglietta, Federica, additional, Vicini, Roberto, additional, D’Amico, Roberto, additional, Balduzzi, Sara, additional, Prat, Aleix, additional, and Guarneri, Valentina, additional

Published
2023
Full Text
View/download PDF

83. Data from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Author

Veeraraghavan, Jamunarani, primary, Gutierrez, Carolina, primary, De Angelis, Carmine, primary, Davis, Robert, primary, Wang, Tao, primary, Pascual, Tomas, primary, Selenica, Pier, primary, Sanchez, Katherine, primary, Nitta, Hiroaki, primary, Kapadia, Monesh, primary, Pavlick, Anne C., primary, Galvan, Patricia, primary, Rexer, Brent, primary, Forero-Torres, Andres, primary, Nanda, Rita, primary, Storniolo, Anna M., primary, Krop, Ian E., primary, Goetz, Matthew P., primary, Nangia, Julie R., primary, Wolff, Antonio C., primary, Weigelt, Britta, primary, Reis-Filho, Jorge S., primary, Hilsenbeck, Susan G., primary, Prat, Aleix, primary, Osborne, C. Kent, primary, Schiff, Rachel, primary, and Rimawi, Mothaffar F., primary

Published
2023
Full Text
View/download PDF

84. Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Author

Veeraraghavan, Jamunarani, primary, Gutierrez, Carolina, primary, De Angelis, Carmine, primary, Davis, Robert, primary, Wang, Tao, primary, Pascual, Tomas, primary, Selenica, Pier, primary, Sanchez, Katherine, primary, Nitta, Hiroaki, primary, Kapadia, Monesh, primary, Pavlick, Anne C., primary, Galvan, Patricia, primary, Rexer, Brent, primary, Forero-Torres, Andres, primary, Nanda, Rita, primary, Storniolo, Anna M., primary, Krop, Ian E., primary, Goetz, Matthew P., primary, Nangia, Julie R., primary, Wolff, Antonio C., primary, Weigelt, Britta, primary, Reis-Filho, Jorge S., primary, Hilsenbeck, Susan G., primary, Prat, Aleix, primary, Osborne, C. Kent, primary, Schiff, Rachel, primary, and Rimawi, Mothaffar F., primary

Published
2023
Full Text
View/download PDF

85. Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Author

Veeraraghavan, Jamunarani, primary, Gutierrez, Carolina, primary, De Angelis, Carmine, primary, Davis, Robert, primary, Wang, Tao, primary, Pascual, Tomas, primary, Selenica, Pier, primary, Sanchez, Katherine, primary, Nitta, Hiroaki, primary, Kapadia, Monesh, primary, Pavlick, Anne C., primary, Galvan, Patricia, primary, Rexer, Brent, primary, Forero-Torres, Andres, primary, Nanda, Rita, primary, Storniolo, Anna M., primary, Krop, Ian E., primary, Goetz, Matthew P., primary, Nangia, Julie R., primary, Wolff, Antonio C., primary, Weigelt, Britta, primary, Reis-Filho, Jorge S., primary, Hilsenbeck, Susan G., primary, Prat, Aleix, primary, Osborne, C. Kent, primary, Schiff, Rachel, primary, and Rimawi, Mothaffar F., primary

Published
2023
Full Text
View/download PDF

86. Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy

Author

Floros, Konstantinos V., Lochmann, Timothy L., Hu, Bin, Monterrubio, Carles, Hughes, Mark T., Wells, Jason D., Morales, Cristina Bernadó, Ghotra, Maninderjit S., Costa, Carlotta, Souers, Andrew J., Boikos, Sosipatros A., Leverson, Joel D., Tan, Ming, Serra, Violeta, Koblinski, Jennifer E., Arribas, Joaquin, Prat, Aleix, Paré, Laia, Miller, Todd W., Dozmorov, Mikhail G., Harada, Hisashi, Windle, Brad E., Scaltriti, Maurizio, and Faber, Anthony C.

Published
2018

87. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

Author

Lambertini, Matteo, Campbell, Christine, Gelber, Richard D., Viale, Giuseppe, McCullough, Ann, Hilbers, Florentine, Korde, Larissa A., Werner, Olena, Chumsri, Saranya, Jackisch, Christian, Wolff, Antonio C., Vaz-Luis, Ines, Ferreira, Arlindo R., Prat, Aleix, Moreno-Aspitia, Alvaro, Piccart, Martine, Loi, Sherene, and de Azambuja, Evandro

Published
2019
Full Text
View/download PDF

89. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Author

Garrido-Castro, Ana C., Saura, Cristina, Barroso-Sousa, Romualdo, Guo, Hao, Ciruelos, Eva, Bermejo, Begoña, Gavilá, Joaquin, Serra, Violeta, Prat, Aleix, Paré, Laia, Céliz, Pamela, Villagrasa, Patricia, Li, Yisheng, Savoie, Jennifer, Xu, Zhan, Arteaga, Carlos L., Krop, Ian E., Solit, David B., Mills, Gordon B., Cantley, Lewis C., Winer, Eric P., Lin, Nancy U., and Rodon, Jordi

Published
2020
Full Text
View/download PDF

90. Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study

Author

Pérez-García, José Manuel, Gebhart, Geraldine, Borrego, Manuel Ruiz, Schmid, Peter, Marmé, Frederik, Prat, Aleix, Dalenc, Florence, Kerrou, Khaldoun, Colleoni, Marco, Braga, Sofía, Malfettone, Andrea, Sampayo-Cordero, Miguel, Cortés, Javier, and Llombart-Cussac, Antonio

Subjects
Adjuvant treatment of cancer, Cancer Research, Receptor, ErbB-2, Breast Neoplasms, General Medicine, Trastuzumab, HER2-positive, Neoadjuvant Therapy, de-escalation, Càncer de mama, pathologic complete response, Breast cancer, Oncology, pertuzumab, Fluorodeoxyglucose F18, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, early breast cancer, FDG-PET, Tractament adjuvant del càncer
Abstract

What is this summary about? This is a summary of a publication about the PHERGain study, which was published in The Lancet Oncology in May 2021. The study includes 376 women with a type of breast cancer called HER2-positive breast cancer that can be removed by surgery. In the study, researchers wanted to learn if participants could be treated with two medicines called trastuzumab and pertuzumab without the need for chemotherapy. To identify HER2-positive tumors with more sensitivity to anti-HER2 therapies, the researchers used a type of imaging called a FDG-PET scan to check how well the treatments were working. What happened in the PHERGain study? Participants took a treatment before surgery, consisting of either chemotherapy (docetaxel and carboplatin) plus trastuzumab and pertuzumab (group A) or trastuzumab and pertuzumab alone (plus hormone therapy if the tumor was hormone receptor-positive; group B). After two cycles of treatment, participants underwent a FDG-PET scan. Participants assigned to group A completed 6 cycles of treatment regardless of 18F-FDG-PET results. Participants in group B continued the same treatment until surgery if their FDG-PET scan showed the treatment was working. While participants who did not show a response started treatment with chemotherapy in addition to trastuzumab and pertuzumab. All participants then had surgery. What were the results? The results revealed that, of the participants in group B who showed a response using FDG-PET scan, 37.9% achieved a disappearance of all invasive cancer in the breast and axillary lymph nodes. This rate appears to be higher than those reported in previous studies evaluating the same treatment. These participants also had less side effects and improved overall quality of life compared with participants taking chemotherapy plus trastuzumab and pertuzumab. What do the results of the study mean? Early monitoring of how well participants respond to treatment by FDG-PET scan seems to identify participants with operable HER2-positive breast cancer who were more likely to benefit from trastuzumab and pertuzumab without the need to have chemotherapy. The PHERGain study is still ongoing and results on long-term survival are expected to be released in 2023. Clinical Trial Registration: NCT03161353 ( ClinicalTrials.gov )

Published
2022

91. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab

Author

Bueno-Muiño, Coralia, primary, Echavarría, Isabel, additional, López-Tarruella, Sara, additional, Roche-Molina, Marta, additional, del Monte-Millán, María, additional, Massarrah, Tatiana, additional, Jerez, Yolanda, additional, Ayala de la Peña, Francisco, additional, García-Sáenz, José Ángel, additional, Moreno, Fernando, additional, Rodríguez-Lescure, Álvaro, additional, Malón-Giménez, Diego, additional, Ballesteros García, Ana Isabel, additional, Marín-Aguilera, Mercedes, additional, Galván, Patricia, additional, Brasó-Maristany, Fara, additional, Waks, Adrienne G., additional, Tolaney, Sara M., additional, Mittendorf, Elizabeth A., additional, Vivancos, Ana, additional, Villagrasa, Patricia, additional, Parker, Joel. S., additional, Perou, Charles M., additional, Paré, Laia, additional, Villacampa, Guillermo, additional, Prat, Aleix, additional, and Martín, Miguel, additional

Published
2023
Full Text
View/download PDF

92. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Author

Tagliamento, Marco, primary, Gennari, Alessandra, additional, Lambertini, Matteo, additional, Salazar, Ramon, additional, Harbeck, Nadia, additional, Del Mastro, Lucia, additional, Aguilar-Company, Juan, additional, Bower, Mark, additional, Sharkey, Rachel, additional, Dalla Pria, Alessia, additional, Plaja, Andrea, additional, Jackson, Amanda, additional, Handford, Jasmine, additional, Sita-Lumsden, Ailsa, additional, Martinez-Vila, Clara, additional, Matas, Marta, additional, Miguel Rodriguez, Ana, additional, Vincenzi, Bruno, additional, Tonini, Giuseppe, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Pedrazzoli, Paolo, additional, D'Avanzo, Francesca, additional, Biello, Federica, additional, Sinclair, Alasdair, additional, Lee, Alvin J.X., additional, Rossi, Sabrina, additional, Rizzo, Gianpiero, additional, Mirallas, Oriol, additional, Pimentel, Isabel, additional, Iglesias, Maria, additional, Sanchez de Torre, Ana, additional, Guida, Annalisa, additional, Berardi, Rossana, additional, Zambelli, Alberto, additional, Tondini, Carlo, additional, Filetti, Marco, additional, Mazzoni, Francesca, additional, Mukherjee, Uma, additional, Diamantis, Nikolaos, additional, Parisi, Alessandro, additional, Aujayeb, Avinash, additional, Prat, Aleix, additional, Libertini, Michela, additional, Grisanti, Salvatore, additional, Rossi, Maura, additional, Zoratto, Federica, additional, Generali, Daniele, additional, Saura, Cristina, additional, Lyman, Gary H., additional, Kuderer, Nicole M., additional, Pinato, David J., additional, and Cortellini, Alessio, additional

Published
2023
Full Text
View/download PDF

93. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Author

Veeraraghavan, Jamunarani, primary, Gutierrez, Carolina, additional, De Angelis, Carmine, additional, Davis, Robert, additional, Wang, Tao, additional, Pascual, Tomas, additional, Selenica, Pier, additional, Sanchez, Katherine, additional, Nitta, Hiroaki, additional, Kapadia, Monesh, additional, Pavlick, Anne C., additional, Galvan, Patricia, additional, Rexer, Brent, additional, Forero-Torres, Andres, additional, Nanda, Rita, additional, Storniolo, Anna M., additional, Krop, Ian E., additional, Goetz, Matthew P., additional, Nangia, Julie R., additional, Wolff, Antonio C., additional, Weigelt, Britta, additional, Reis-Filho, Jorge S., additional, Hilsenbeck, Susan G., additional, Prat, Aleix, additional, Osborne, C. Kent, additional, Schiff, Rachel, additional, and Rimawi, Mothaffar F., additional

Published
2023
Full Text
View/download PDF

94. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer

Author

Olivera-Salguero, Rubén, primary, Seguí, Elia, additional, Cejalvo, Juan Miguel, additional, Oliveira, Mafalda, additional, Tolosa, Pablo, additional, Vidal, Maria, additional, Malumbres, Marcos, additional, Gavilá, Joaquín, additional, Saura, Cristina, additional, Pernas, Sonia, additional, López, Rafael, additional, Margelí, Mireia, additional, Balmaña, Judith, additional, Muñoz, Montserrat, additional, Blancas, Isabel, additional, Boni, Valentina, additional, Ciruelos, Eva, additional, Galve, Elena, additional, Perelló, Antonia, additional, Sánchez-Bayona, Rodrigo, additional, de la Cruz, Susana, additional, de la Hoya, Miguel, additional, Galván, Patricia, additional, Sanfeliu, Esther, additional, Gonzalez-Farre, Blanca, additional, Sirenko, Valeria, additional, Blanch-Torras, Aura, additional, Canes, Jordi, additional, Masanas, Helena, additional, Olmos, Rosa, additional, Forns, Margarita, additional, Prat, Aleix, additional, Casas, Ana, additional, and Pascual, Tomás, additional

Published
2023
Full Text
View/download PDF

95. Data from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Author

Ibrahim, Yasir H., primary, García-García, Celina, primary, Serra, Violeta, primary, He, Lei, primary, Torres-Lockhart, Kristine, primary, Prat, Aleix, primary, Anton, Pilar, primary, Cozar, Patricia, primary, Guzmán, Marta, primary, Grueso, Judit, primary, Rodríguez, Olga, primary, Calvo, Maria Teresa, primary, Aura, Claudia, primary, Díez, Orland, primary, Rubio, Isabel T., primary, Pérez, José, primary, Rodón, Jordi, primary, Cortés, Javier, primary, Ellisen, Leif W., primary, Scaltriti, Maurizio, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

96. Supplementary Figure Legends 1-6, Table Legend 1 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Author

Ibrahim, Yasir H., primary, García-García, Celina, primary, Serra, Violeta, primary, He, Lei, primary, Torres-Lockhart, Kristine, primary, Prat, Aleix, primary, Anton, Pilar, primary, Cozar, Patricia, primary, Guzmán, Marta, primary, Grueso, Judit, primary, Rodríguez, Olga, primary, Calvo, Maria Teresa, primary, Aura, Claudia, primary, Díez, Orland, primary, Rubio, Isabel T., primary, Pérez, José, primary, Rodón, Jordi, primary, Cortés, Javier, primary, Ellisen, Leif W., primary, Scaltriti, Maurizio, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

97. Supplementary Figure S6 from The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

Author

Gómez-Miragaya, Jorge, primary, Morán, Sebastián, primary, Calleja-Cervantes, Maria Eréndira, primary, Collado-Sole, Alejandro, primary, Paré, Laia, primary, Gómez, Antonio, primary, Serra, Violeta, primary, Dobrolecki, Lacey E., primary, Lewis, Michael T., primary, Diaz-Lagares, Angel, primary, Eroles, Pilar, primary, Prat, Aleix, primary, Esteller, Manel, primary, and González-Suárez, Eva, primary

Published
2023
Full Text
View/download PDF

98. Supplementary Table S1 from The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

Author

Gómez-Miragaya, Jorge, primary, Morán, Sebastián, primary, Calleja-Cervantes, Maria Eréndira, primary, Collado-Sole, Alejandro, primary, Paré, Laia, primary, Gómez, Antonio, primary, Serra, Violeta, primary, Dobrolecki, Lacey E., primary, Lewis, Michael T., primary, Diaz-Lagares, Angel, primary, Eroles, Pilar, primary, Prat, Aleix, primary, Esteller, Manel, primary, and González-Suárez, Eva, primary

Published
2023
Full Text
View/download PDF

99. Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

Author

Pinato, David J., primary, Zambelli, Alberto, primary, Aguilar-Company, Juan, primary, Bower, Mark, primary, Sng, Christopher C.T., primary, Salazar, Ramon, primary, Bertuzzi, Alexia, primary, Brunet, Joan, primary, Mesia, Ricard, primary, Seguí, Elia, primary, Biello, Federica, primary, Generali, Daniele, primary, Grisanti, Salvatore, primary, Rizzo, Gianpiero, primary, Libertini, Michela, primary, Maconi, Antonio, primary, Harbeck, Nadia, primary, Vincenzi, Bruno, primary, Bertulli, Rossella, primary, Ottaviani, Diego, primary, Carbó, Anna, primary, Bruna, Riccardo, primary, Benafif, Sarah, primary, Marrari, Andrea, primary, Wuerstlein, Rachel, primary, Carmona-Garcia, M. Carmen, primary, Chopra, Neha, primary, Tondini, Carlo, primary, Mirallas, Oriol, primary, Tovazzi, Valeria, primary, Betti, Marta, primary, Provenzano, Salvatore, primary, Fotia, Vittoria, primary, Cruz, Claudia Andrea, primary, Dalla Pria, Alessia, primary, D'Avanzo, Francesca, primary, Evans, Joanne S., primary, Saoudi-Gonzalez, Nadia, primary, Felip, Eudald, primary, Galazi, Myria, primary, Garcia-Fructuoso, Isabel, primary, Lee, Alvin J.X., primary, Newsom-Davis, Thomas, primary, Patriarca, Andrea, primary, García-Illescas, David, primary, Reyes, Roxana, primary, Dileo, Palma, primary, Sharkey, Rachel, primary, Wong, Yien Ning Sophia, primary, Ferrante, Daniela, primary, Marco-Hernández, Javier, primary, Sureda, Anna, primary, Maluquer, Clara, primary, Ruiz-Camps, Isabel, primary, Gaidano, Gianluca, primary, Rimassa, Lorenza, primary, Chiudinelli, Lorenzo, primary, Izuzquiza, Macarena, primary, Cabirta, Alba, primary, Franchi, Michela, primary, Santoro, Armando, primary, Prat, Aleix, primary, Tabernero, Josep, primary, Gennari, Alessandra, primary, Avanzi, Gian Carlo, primary, Bellan, Mattia, primary, Castello, Luigi Mario, primary, Martinez, Maria, primary, Mollà, Meritxell, primary, Pirisi, Mario, primary, Scotti, Lorenza, primary, and Swallow, Judith, primary

Published
2023
Full Text
View/download PDF

100. Supplementary Figure 6 from PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Author

Ibrahim, Yasir H., primary, García-García, Celina, primary, Serra, Violeta, primary, He, Lei, primary, Torres-Lockhart, Kristine, primary, Prat, Aleix, primary, Anton, Pilar, primary, Cozar, Patricia, primary, Guzmán, Marta, primary, Grueso, Judit, primary, Rodríguez, Olga, primary, Calvo, Maria Teresa, primary, Aura, Claudia, primary, Díez, Orland, primary, Rubio, Isabel T., primary, Pérez, José, primary, Rodón, Jordi, primary, Cortés, Javier, primary, Ellisen, Leif W., primary, Scaltriti, Maurizio, primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results